<DOC>
	<DOCNO>NCT01511172</DOCNO>
	<brief_summary>This trial conduct Europe Oceania . The aim trial ass effect glycemic control NNC 90-1170 ( liraglutide ) add metformin compare metformin give alone subject type 2 diabetes previously treat OHAs ( oral hypoglycaemic agent ) .</brief_summary>
	<brief_title>Effect Liraglutide add-on Metformin Compared Either Liraglutide Metformin Alone , Combination Metformin SU ( Sulphonylurea ) Agent Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients diagnose type 2 diabetes treat least 50 % maximum dose ( ) OHA ( ) least three month Duration type 2 diabetes diagnosis least one year HbA1c 8.013.0 % , inclusive Body Mass Index ( BMI ) 2540 kg/m^2 , inclusive . Current treatment thiazolidinediones insulin initiate within last four month prior trial Impaired liver function Impaired renal function Cardiac problem Uncontrolled treated/untreated hypertension Cancer clinically significant disease disorder , except condition associate type 2 diabetes , Investigator 's opinion could interfere result trial Recurrent major hypoglycaemia judge Investigator Known suspect allergy trial product relate product Use drug ( except OHAs ) , Investigator 's opinion could interfere glucose level Known suspect abuse alcohol narcotic Any contraindication metformin glimepiride accord local guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>